Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Enterprise Value: 2018-2024

Historic Enterprise Value for Kiniksa Pharmaceuticals International (KNSA) over the last 7 years, with Dec 2024 value amounting to $1.2 billion.

  • Kiniksa Pharmaceuticals International's Enterprise Value rose 64.19% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 117.09%. This contributed to the annual value of $1.2 billion for FY2024, which is 15.30% up from last year.
  • According to the latest figures from FY2024, Kiniksa Pharmaceuticals International's Enterprise Value is $1.2 billion, which was up 15.30% from $1.0 billion recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Enterprise Value's 5-year high stood at $1.2 billion during FY2020, with a 5-year trough of $628.6 million in FY2021.
  • Moreover, its 3-year median value for Enterprise Value was $1.0 billion (2023), whereas its average is $1.0 billion.
  • Its Enterprise Value has fluctuated over the past 5 years, first slumped by 47.74% in 2021, then spiked by 35.37% in 2022.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Enterprise Value (Yearly) stood at $1.2 billion in 2020, then crashed by 47.74% to $628.6 million in 2021, then spiked by 35.37% to $851.0 million in 2022, then grew by 20.73% to $1.0 billion in 2023, then increased by 15.30% to $1.2 billion in 2024.